Eli Lilly & Co. said a U.S.-run clinical trial of its experimental antibody therapy will end after data suggested the treatment is unlikely to help hospitalized patients recover from advanced disease. AstraZeneca Plc’s vaccine candidate produced a robust immune response in elderly people.
More Stories
Record Korean Cases; Trader’s Guide to Rollout: Virus Update
California Hits Record; Trader’s Guide to Rollout: Virus Update
AstraZeneca to Buy Alexion for $39 Billion in Rare-Disease Push